Distant/virtual pharmacovigilance inspections of MAHs during a crisis situation- Points to consider



Similar documents
EU Clinical Trials Register. An agency of the European Union

Reflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/GMP Compliance Problems

Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials

Submission of comments on 'Policy 0070 on publication and access to clinical-trial data'

Adoption by GCP Inspectors Working Group for consultation 14 June End of consultation (deadline for comments) 15 February 2012

Questions and answers on post approval change management protocols

Work instructions. 1. Changes since last revision. 2. Records. 3. Instructions. Title: How to create reports from scientific memory database (SMD)

Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies

One-year report on human medicines pharmacovigilance tasks of the European Medicines Agency

Regulatory approval routes in the European System for Medicinal Products

EMA esignature capabilities: frequently asked questions relating to practical and technical aspects of the implementation

Guideline on Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs)

Questions and answers on post approval change management protocols

Standard operating procedure

Questions & answers on signal management

End of consultation (deadline for comments) 14 October Adoption by Committee for advanced therapies 15 October 2010

Reflection paper on non-spontaneous adverse event reports (peer-reviewed literature, internet and social media)

Questions and answers on preparation, management and assessment of periodic safety update reports (PSURs)

Work instructions. 1. Changes since last revision. 2. Records. 3. Instructions EXPLANATORY NOTES

Compilation of Community Procedures on Inspections and Exchange of Information

Annex VI Service Level Agreement for Medical Service Provider

PROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA. GCP Inspectors Working Group

BEST PRACTICE GUIDE for Handling of Periodic Safety Update Reports

Data submission of authorised medicines in the European Union

POST-AUTHORISATION GUIDANCE. Human Medicinal Products

Adoption by CHMP for release for consultation November End of consultation (deadline for comments) 31 March 2011

EMA Update Clinical Trials

Questions and answers relating to Open Tender EMA/2012/21/IS

Standard operating procedure

ICH guideline Q8, Q9 and Q10 - questions and answers volume 4

How to search the EU Clinical Trials Register

Implementation strategy for ISO IDMP in EU

All the steps detailed in this WIN are carried out by the assistant in the Sampling and Testing Team in the MQC Section.

European Medicines Agency decision

II. AREA OF INVOLVEMENT OF PATIENTS AND CONSUMERS IN EMEA ACTIVITIES

Reflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical trials

Report to the European Commission on Pharmacovigilance audits carried out in the Medicines Evaluation Board, The Netherlands period of time from

Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples

New access models for the buy side ISA DIRECT

Work plan for GMP/GDP Inspectors Working Group for 2016

The EMA current activities towards ISO IDMP implementation

Guideline on Process Validation

EudraVigilance stakeholder change management plan

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)

Standard operating procedure

Opinion/ Commission. Notification 1. Decision. Information issued on. Issued 2 / affected 3 amended on

Strategy and pilot phase for patient registries

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS

extended EudraVigilance Medicinal Product Dictionary (XEVMPD) Data-Entry Tool (EVWEB) user manual

QRD recommendations on pack design and labelling for centrally authorised non-prescription human medicinal products

Quick Response (QR) codes in the labelling and package leaflet of centrally authorised 1 medicinal products

EU PAS Register Guide

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

Guideline on stability testing for applications for variations to a marketing authorisation

The European regulatory system for medicines and the European Medicines Agency

Clinical trials submitted in marketing-authorisation applications to the European Medicines Agency

The Application and Inspection Process What to Expect

GCP INSPECTORS WORKING GROUP <DRAFT> REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS

Guideline on good pharmacovigilance practices (GVP)

Compilation of individual product-specific guidance on demonstration of bioequivalence

30 Churchill Place: Orientation guide for staff EMA/151278/2015 Page 1/11

Guidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes

Reflection paper on clinical aspects related to tissue engineered products

EUDRAVIGILANCE TELEMATICS IMPLEMENTATION GROUP

The EU Clinical Trial Regulation A regulator s perspective

Discussion Paper on the Validation of Pharmacovigilance Software provided via SaaS

EMA/AD/354: Head of Human Resources, Administration Division (AD10)

EU Change Control Process for Change Requests in the Entire Area of Electronic Submissions for Human Medicinal Products Version 2.

CMD(v)/GUI/014. GUIDANCE for The Processing of Generic Applications Through MRP / DCP

ICH guideline E2C (R2) Periodic benefit-risk evaluation report (PBRER)

Questions and answers on serious non-fatal adverse events and reporting rules

Standard operating procedure

EMA/AD/376: Scientific Officer, Compliance and Inspections, Inspections and Human Medicines Pharmacovigilance Division (AD8)

Adopted by CHMP in November Revision 1.0 adopted by CHMP on 25 June 2009

Guideline on good pharmacovigilance practices (GVP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

MedDRA in pharmacovigilance industry perspective

Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies

ICH guideline Q10 on pharmaceutical quality system

Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes

In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:

THE ACTIVITIES AND FUTURE DEVELOPMENT OF GCP INSPECTIONS IN TANZANIA

Opinion/ Commission. Notification. Decision. Issued 2 / affected 3 amended on. 30/07/2015 Annex II, Labelling and PL

Incident Management & Communications. Top 8 Focus Areas to Mitigate Risk

Compilation of Community Procedures on Inspections and Exchange of Information

Memorandum of Understanding between the Financial Conduct Authority and the Bank of England, including the Prudential Regulation Authority

Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON DATA MONITORING COMMITTEES

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Reflection paper on risk based quality management in clinical trials

The EU portal and database

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

EDQM Certificates of Suitability: Cooperation Among Inspectorates in Europe And Beyond

Transcription:

18 January 2013 EMA/INS/119905/2012 Compliance and Inspection Distant/virtual pharmacovigilance inspections of MAHs during a crisis situation- Points This document is intended to provide guidance on the steps to be followed during distant / virtual pharmacovigilance (PhV) inspections of MAHs. Agreed by PhV IWG 14 December 2012 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8594 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged.

Table of contents 1. Introduction... 3 2. Inspection announcement... 3 3. Preparation of the inspection... 3 3.1. Technical preparation... 3 3.1.1. Communication... 3 3.1.2. Provision of documents... 3 3.2. Documentation preparation... 4 3.3. Conduct preparation... 4 4. Conduct phase... 4 5. Post-inspection... 5 6. Reporting of inspections... 5 EMA/INS/119905/2012 Page 2/5

1. Introduction The necessity to be able to perform pharmacovigilance inspections during crisis situations has been identified as an important issue. Under situations such as transport restrictions or situations which give rise to concerns of inspectors safety (e.g. pandemics, natural disasters, high criminality areas), distant/virtual inspections could replace on site inspections. The inspectorate, in agreement with the committee requesting the inspection, should decide on a case by case basis whether a distant/virtual inspection will prove sufficient to gain an adequate overview of the functioning of the MAH s PhV system or not (e.g. in the case that the MAH is high risk based on intelligence information a virtual inspection may not be adequate on its own). Distant/virtual inspections should follow the guidelines that already exist for the conduct of PhV inspections, but should take ination the limitations imposed by using a virtual process. It is the purpose of this document to outline the specificities of distant/virtual PhV inspections identifying the points that should be considered during the preparation and conduct of such PhV inspections. 2. Inspection announcement In the inspection announcement letter, the technical requirements (means of communication) as well as the preparation procedure, including a list of documents required pre-inspection, should be clearly described. The importance of the timely provision of all necessary documentation as well as a robust set-up of the virtual facilities, should be stressed. 3. Preparation of the inspection 3.1. Technical preparation 3.1.1. Communication Due to the nature of this type of inspection, direct contact with company personnel is likely to be minimal or non-existent. It is imperative that reliable tele-conference facilities are available during the inspection. They are likely to form a larger part of the inspection, which should be taken ination for the length of the inspection. If possible, the telecommunications arrangements should be tested in advance. 3.1.2. Provision of documents There will be greater difficulties in obtaining documentation in a timely manner compared to an inspection at company offices. Considerations should include: Discussion and agreement of the document request process in advance. Arrangement for documents to be requested and sent by Eudralink or through the agency portal if applicable. EMA/INS/119905/2012 Page 3/5

3.2. Documentation preparation More documentation should be requested pre-inspection (requests could be sent in the announcement letter). Pre-empting routine requests can save time during the inspection. Some documentation may require translation (the burden on the MAH should be considered and only translation of key documents should be requested). The amount of documentation to be reviewed should be decided in advance. Performing extensive document review in advance may assist one to ask targeted interview questions. It may be appropriate to add a day to the inspection to review documentation during the inspection and subsequently conduct more focussed interviews. Listings and case files should be requested in advance / prior to the inspection. For product-specific triggered inspections, involving the assessor in document requests and line listing/case reviews may be important. If the inspection is performed at the office of the regulatory authority, there may be more opportunity to involve assessors. 3.3. Conduct preparation The following points should be considered: Has another NCA Inspectorate inspected the MAH PV system? Where appropriate for e.g. triggered inspections, a summary of the inspection findings of GCP/GMP inspections from relevant competent authorities could be requested. The inspection should be tailored, as appropriate, in accordance with what may already have been reviewed by another authority. Relevant intelligence information should be reviewed e.g. compliance data, communications from worldwide authorities (e.g. FDA Warning Letters) etc. The process by which company personnel are to obtain documents during the inspection should be considered. One way would be to ensure internet access and those documents required to be in hardcopy could be e-mailed (Eudralink) or sent through the agency portal (if applicable) and printed by CA s Admin staff/inspection team. The interviewees language abilities should be considered prior to the inspection. An agenda (plan) for the inspection, which accounts for time for telephone discussions and time for reviewing documents offline, should be prepared. Actual times for discussions will need to be scheduled. If the inspection is triggered and product-specific, involvement of the relevant assessor(s) in the inspection should be considered. 4. Conduct phase A good internet connection is essential for document review using a laptop. However, it is useful to save key documents on to a USB pen (ensuring confidentiality), in case the wireless connection is disrupted. All documents used should be exchanged and stored in way that ensures confidentiality. If there are problems encountered with communication during the conduct of the inspection e.g. internet connection problems, language issues, the inspectors could consider asking fewer questions, conducting fewer interviews and reviewing more documentation in order to confirm EMA/INS/119905/2012 Page 4/5

activities. Sometimes the use of a translator may be helpful, but this adds substantially to the time needed to conduct the interview. General points should be considered with respect to teleconference interviews i.e. Speak slower in order to be clearly understood, If more than one inspector/assessor is in the room, agree some signals to indicate when you wish to interrupt or when you wish to place the call on mute, Repeat and summarise where necessary in order to confirm understanding. MAH personnel should not have to be on teleconference throughout, thus specific times for interviews and to follow-up issues should be arranged. Any time difference (where relevant) should be considered allowing for breaks during long interviews. Additional days may be needed to be added to the virtual inspection, perhaps after additional documents have been requested and reviewed. 5. Post-inspection If it is believed that significant issues have been identified that have not been able to be adequately reviewed during a virtual inspection, other options should be considered e.g. If considered necessary and if practical, an inspection of the MAH s pharmacovigilance headquarters should be arranged. 6. Reporting of inspections The procedure for reporting such inspections will follow the same procedure as for the face-to-face inspections, clearly indicating what was and what was not covered during the virtual inspection. EMA/INS/119905/2012 Page 5/5